Who We Fund

Investing in Industry and Academic Research

We have awarded more than $20 million in brain tumor research funding to world-renowned research investigators and physician-scientists from 46 institutions. We don't view ourselves as simply investors, we are value-added partners with medical research centers, early-stage biotechnology companies and large multi-national pharmaceutical companies.  We help shape the direction of the research and move treatments as fast as possible from basic discovery to the clinic. 

For more information on our current projects, please click here.

Investments in Industry

  • Agios

    ABC2’s investment provided the support Agios needed to move its cancer metabolism project into brain cancer. Prior to our involvement, Agios focused exclusively on leukemia research.

  • Exosome Diagnostics

    ABC2 and Exosome Diagnostics are collaborating with two leading academic research centers to accelerate the clinical validation of Exosome Diagnostic's biofluid-based diagnostic technology.

  • Novartis

    We are working with Novartis, Henry Ford Hospital, and Columbia University to develop state-of-the-art model systems to id

  • Genentech

    ABC2 funded Genentech’s early stage research and clinical trial work to test and develop the drug Avastin to treat brain cancer patients.

  • Regulus Therapeutics

    Regulus is now working with Samsung Medical Center to develop a microRNA therapeutic to target the “master control switches” in brain tumors.

  • Tocagen

    ABC2 was the first non-profit organization to fund Tocagen, a biotech company that was able to then go onto raise additional funding for their groundbreaking therapy.

Brain Tumor Research Grants

  • Johns Hopkins

    We are funding a clinical trial at Johns Hopkins to test whether mebendazole, a drug already approved by the FDA to fight

  • UCSD & Regulus

    Early detection of tumor recurrence remains one of the greatest challenges in the treatment of brain cancer. 

  • Split Immunity Research

    We're funding the innovative work by researchers at Tel Aviv Sourasky Medical Center.

  • UCSF

    We are funding a UCSF project to understand the effects of temozolomide on low-grade gliomas.

  • FCBTR/ABC2 Grants

    Together, since 2010, FCBTR and ABC2 have together funded more than $925,000 in Florida-based brain tumor research

  • Duke Medicine

    Duke Medicine and Accelerate Brain Cancer Cure have worked together to advance treatments since 2001. We've funded 25 different projects by Duke investigators.

  • DIPG

    Our investment and scientific guidance is helping to advance the work of an international consortium working on a treatment for a rare pediatric brain tumor called diffuse intrinsic pontine glioma (DIPG).

  • Broad/Dana-Farber

    We are funding whole exome sequencing of brain tumors at the Broad Institute to advance research at Dana-Farber on the personalized NeoVax immunotherapy treatment.

  • UCLA

    We are funding the development of a clinical trial to determine if retinoic acid -- Accutane -- might be an effective brain cancer treatment for patients with IDH gene mutations.

  • Mayo Clinic / T-Gen

    ABC2’s investment helps move forward a novel personalized medicine trial for glioblastoma patients led by Mayo Clinic, one of the leading clinical centers, and TGen, a cutting edge genomics lab.

Share |

Join us in our fight for a cure!